Alerta

PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY

Resumen de: AU2023329399A1

The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.

COMPOSITION FOR PREVENTING OR TREATING LUPUS, COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN

Resumen de: AU2023334485A1

The present invention relates to a composition for preventing or treating lupus or glomerulonephritis, comprising a recombinant stabilized galectin 9 protein. Specifically, it was confirmed that the recombinant stabilized galectin 9 protein of the present invention shows safety in a systemic lupus erythematosus (SLE) animal model, reduces skin lesions, lymphadenopathy, and proteinuria caused by lupus, alleviates lupus nephritis and glomerulonephritis, and shows the effect of reducing the concentration of anti-dsDNA antibodies in plasma. Therefore, the recombinant stabilized galectin 9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.

HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF

Resumen de: US2025084076A1

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.

POLYPEPTIDE HAVING EFFECT OF INHIBITING PROLIFERATION OF LEUKEMIA CELLS

Resumen de: US2025084138A1

The present disclosure discloses a polypeptide having an effect of inhibiting the proliferation of leukemia cells, and particularly relates to use of the polypeptide in a drug for treating leukemia. The polypeptide consists of 37 amino acids, with the amino acid sequence thereof being Lys-Glu-Ser-Met-Asp-Ala-Asn-Lys-Pro-Thr-Lys-Asn-Leu-Pro-Leu-Lys-Lys-Ile-Pro-Cys-Lys-Thr-Ser-Ala-Pro-Ser-Gln-Ser-Phe-Phe-Ala-Arg-Asp-Asn-Thr-Ala-Asn, and the N-terminus of the polypeptide being conjugated with myristate. The polypeptide prepared by the present disclosure can enter the leukemia cells by conjugating with the myristic acid, thereby achieving the effect of inhibiting the proliferation of the leukemic cells.

PHARMACEUTICAL COMPOSITION FOR TREATING LYMPHOMA

Resumen de: AU2022476501A1

Provided is a method for treating lymphoma.　Use is made of a composition for treating lymphoma, the composition containing BCV, a pharmaceutically acceptable salt thereof, or a solvate of the BCV or the salt thereof. The lymphoma may be MYC-positive lymphoma. The lymphoma may be EBV-positive lymphoma. The pharmaceutical composition may be used together with a chemotherapeutic agent.

4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES

Resumen de: US2025084039A1

This invention relates to 4-substituted isoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.

ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE

Resumen de: US2025082629A1

Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma. The second active agent is one or more of a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an MEK inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BRD4 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a BIRC5 inhibitor, a BET inhibitor, or a DNA methyltransferase inhibitor.

SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES

Resumen de: US2025082652A1

The present invention pertains to the treatment of proliferative diseases, such as cancer. In particular, the invention describes a novel combination therapy strategy, comprising a Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, an Inhibitor of κB (IκB) Kinase (IKK)/Nuclear Factor κB (NFκB)-signaling inhibitor, and a B-cell lymphoma 2 (BCL-2) inhibitor for the treatment and/or prevention of proliferative diseases, such as cancer. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention. The invention further pertains to a method of treatment and/or prevention of a proliferative disease in a subject, the method comprising administering to the subject as single treatments or one or more combinatorial treatments, either sequentially or concomitantly, a therapeutically effective amount of inhibitors of RIPK1, inhibitors of IKK/NFκB-signalling, and inhibitors of BCL-2.

CHIMERIC ANTIGEN RECEPTORS FOR TREATMENT OF CANCER

Resumen de: US2025082755A1

Provided herein are chimeric antigen receptors (CARs) with binding specificity for CD123. Nucleic acids, expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed, and methods including the treatment of a hematopoietic malignancy or premalignancy characterized by the expression of CD123, e.g., leukemias such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

GEP5 MODEL FOR MULTIPLE MYELOMA

Resumen de: US2025084485A1

The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.

ANAPLASTIC LYMPHOMA KINASE (ALK) CANCER VACCINES AND METHODS OF USE THEREOF

Resumen de: US2025057930A1

The invention features compositions and methods for treating anaplastic lymphoma kinase (ALK)-rearranged neoplasias including Non-Small Cell Lung Cancers (NSCLCs). The methods involve administering to a subject ALK peptides and/or polynucleotides encoding the ALK peptides, optionally in combination with an immune checkpoint inhibitor (ICI) and/or an ALK tyrosine kinase inhibitor (TKI).

METHODS FOR TREATING LYMPHOMA

Resumen de: AU2023264582A1

Provided herein, in certain aspects, are methods for the treatment of lymphoma, comprising administration of a CD19 antibody, a CD3xCD20 multispecific antibody, and 3-(4- amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl) piperidine-2, 6-dione (Compound A).

BENZIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS

Resumen de: WO2025048759A1

The present invention pertains to benzimidazole derivatives of formula (I) and their inhibitory activity against mPGES-1. It also encompasses pharmaceutical compositions that include these benzimidazole derivatives and their application in treating mPGES-1-mediated diseases. The purpose of this invention is to create novel compounds that inhibit inducible mPGES-1, an enzyme responsible for catalyzing the final step in the biosynthesis of PGE2 from AA. These compounds are intended for the treatment of various inflammatory conditions, including but not limited to Parkinson's disease, autoimmune diseases, allergic disorders, rhinitis, coronary heart disease, ulcers, osteoarthritis, rheumatoid arthritis, systemic sclerosis, periodontitis, colon cancer, inflammatory bowel disease, cutaneous sclerosis, neuropathic pain, inflammation, pain, fever, migraine, chronic pain, acute pain, headache, asthma, pulmonary fibrosis, fibromyalgia, dysmenorrhea, atherosclerosis, gout, arthritis, rheumatic fever, multiple sclerosis, Hodgkin's disease.

METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION

Resumen de: WO2025049966A2

Disclosed are methods of increasing R0R1 in a cell comprising administering an EZH2 inhibitor, G9A inhibitor, DNMT1 inhibitor or combination thereof to the cell. Disclosed are methods of treating lymphoma in a subject comprising administering to the subject one or more EZH2 inhibitors, G9A inhibitors, DNMT1 inhibitors or combinations thereof, wherein the one or more EZH2 inhibitors, G9A inhibitors, DNMT1 inhibitors or combinations thereof increase expression of R0R1 in one or more B cells in the subject; and one or more R0R1 targeting therapeutics.

BISPECIFIC ANTIBODIES AND USES THEREOF

Resumen de: US2025074982A1

Provided herein are, inter alia, antibody compounds comprising an anti-immune cell antibody (e.g., anti-CD3 antibody) covalently bound to a CS-1-binding antibody; immune cells bound to compounds comprising an anti-immune cell antibody (e.g., anti-CD3 antibody) covalently bound to a CS-1-binding antibody; humanized OKT3 antibodies; pharmaceutical compositions; and methods for treating cancer, such as multiple myeloma.

TREATMENT OF NON SMALL CELL LUNG CANCER WITH ALECTINIB

Resumen de: WO2025045901A1

The present invention relates to a method of treating anaplastic lymphoma kinase (ALK)- positive non-small cell lung cancer (NSCLC), comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject has resected stage Ib ALK-positive NSCLC with a tumour greater or equal to 4cm to stage IIIa ALK-positive NSCLC.

REAGENTS AGAINST HUMAN ENDOGENOUS RETROVIRUSES TO TARGET CANCER CELLS

Resumen de: WO2025046393A1

The present invention relates to affinity reagents that are capable of specifically binding to a surface antigen of a virus belonging to the family of human endogenous retroviruses (HERV), in particular to a HERV envelope protein, for use in the prophylactic and/or therapeutic treatment of a cancer in a subject in need thereof. The invention relates also to the use of such affinity reagents in the diagnosis or prognosis of cancer, in particular lymphoma.

NOVEL DARPIN BASED CD70 ENGAGERS

Resumen de: US2025074994A1

The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain, wherein the ankyrin repeat domain has binding specificity for human CD70. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g., acute myeloid leukemia (AML), in a mammal, including a human.

CHEMO-SENSITIVE DOMINANT CLONE FOR ADAPTIVE THERAPY

Resumen de: WO2025049877A1

Disclosed herein is a system that addresses all of the current challenges described above by combining three existing technologies and an improved nuclear RNA delivery system to generate a first-in-class cellular therapy that can secrete a cancer specific suicide gene for the treatment of several cancers. Also disclosed herein is a 'Trojan-Horse' like genetic construct aimed at engineering a chemo-sensitive dominant clone for adaptive therapy in cancers, such as leukemia. In some embodiments, cells, such as cancer cells from a subject, are engineered with suicide genes to promote a bystander effect in neighboring cancer cells once returned to the subject. In some embodiments, these cells are further engineered to be clonally dominant, e.g. by deleting or mutating tumor suppressor genes in the cells, overexpressing oncogenes, or any combination thereof. Once the engineered cells have reached a target clonal dominance, the suicide gene can be induced, thereby promoting the bystander effect.

METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES

Resumen de: US2025073212A1

Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.

COMBINATIONS OF LSD1 INHIBITORS FOR TREATING MYELOID CANCERS

Resumen de: US2025073232A1

The instant invention relates to combinations of LSD1 inhibitors (or pharmaceutically acceptable salts thereof) and gilteritinib (or a pharmaceutically acceptable salt thereof). The combinations are particularly useful for treating myeloid cancers, such as acute myeloid leukemia or myelodysplastic syndrome.

DOSING REGIMENS FOR CANCER IMMUNOTHERAPY

Resumen de: US2025073266A1

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cells express a chimeric receptor that targets ligands of NKG2D on tumor cells. In several embodiments, the cancer is a blood cancer, for example, acute myeloid leukemia (e.g., relapsed/refractory acute myeloid leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, for example, intrahepatic cholangiocarcinoma or other liver tumor, for example, secondary metastases from colorectal cancer.

METHODS FOR TREATING CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES

Resumen de: US2025073274A1

Provided are methods for treating a CD33-positive hematological malignancy, such as acute myelogenous leukemia or multiple myeloma, in a subject by administering to the subject hematopoietic stem cells (HSCs) or hematopoietic stem and progenitor cells (HSPCs) genetically modified to reduce or eliminate CD33 expression in myeloid cells derived therefrom in conjunction with antibody radioconjugates for one or both of conditioning the subject's bone marrow to receive and engraft the genetically modified stem cells and selectively depleting the subject's endogenous CD33-positive cells, including CD33-positive malignant cells.

METHODS OF TREATING MULTIPLE MYELOMA USING BCL-2 INHIBITOR

Resumen de: AU2023309181A1

The present disclosure provides methods of treating multiple myeloma in a subject with a Bcl-2 inhibitor, in particularly 2- ( (1H-pyrrolo 2, 3-b pyridin-5-yl) oxy) -N- ( (4- ( ( ( (1r, 4r) -4-hydroxy-4-methylcyclohexyl) methyl) amino) -3-nitrophenyl) sulfonyl) -4- (2- ( (S) -2- (2-isopropylphenyl) pyrrolidin-1-yl) -7-azaspiro 3.5 nonan-7-yl) benzamide or a pharmaceutically acceptable salt thereof, or in combination with dexamethasone.

SURVIVIN MRNA VACCINE

Nº publicación: WO2025049442A1 06/03/2025

Solicitante:

H LEE MOFFITT CANCER CENTER AND RES INSTITUTE INC [US]
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC